Zhitai Pharmaceutical

(METiS Pharmaceuticals), a leading global artificial intelligence (AI)-drivenDrug deliveryThe company was founded and led by Dr. Hongmin Chen, a member of the U.S. Academy of Engineering, and Dr. Caida Lai, a leading scientist at MIT. The company was founded and led by Hongmin Chen, a member of the U.S. Academy of Engineering, as well as top MIT scientists Dr. Caida Lai and Dr. Wenshou Wang, with a core team of drug discovery experts from well-known pharmaceutical companies such as Novartis, Amgen and Regenerative Element, as well as young up-and-comers in AI, computing and other areas. DynaTech aims to combine new AI technology with traditional drug development to promote innovative drug development more efficiently and accurately, and at the same time utilize its core technology platform to empower the pharmaceutical ecosystem and lead the industry in innovation.

Service Areas

DoseTech Pharma's service areas are focused on driving drug delivery and drug discovery through AI technologies, addressing unmet clinical needs and driving optimal therapies across a broad range of disease areas. The company integrates cross-disciplinary technologies such as AI, quantum simulation and high-throughput experimental platforms to build its unique AiLNP, AiRNA and AiTEM core technology platforms, in order to predict the physicochemical and biological properties of small molecule and nucleic acid drugs in specific microenvironments, to achieve more effective design of innovative delivery materials, design and optimization of nucleic acid sequences, and to design more advantageous formulation formulations or nucleic acid delivery systems.

Main products

DynaTech Pharma has now built more than ten product development pipelines, including RNA drugs and small molecule new drugs. The company carries out in-depth cooperation with top domestic and foreign pharmaceutical companies through co-development of pipelines or cooperation through external licensing of technology platforms.

Core Advantages

1. World's Leading Technology: DoseTech Pharma is the first company to apply AI technology to drug formulation development and drug delivery, and its core technology platform, AiLNP, is also the world's first innovative platform for LNP vector design with AI algorithms to drive mRNA delivery.
2. Wide range of design spaces: Using the empowerment of AI and machine learning, DynaTech has realized the exploration of the "global" design space, from the 2,000 to 3,000 lipids reported in the current documented patents, to the chemical space of over a million levels of lipid design.
3. continuous innovation: The company continues to lead the industry by more than an order of magnitude by iterating on new materials that target different organs on a monthly basis.
4. Industry RecognitionWith excellent technology and strength, DynaTech was honored with the title of "2023 Innovative Healthcare Company" and became a leading company in the field of "AI+Drug Delivery".
5. capitalist favorThe company was founded three years ago and has received nearly $200 million in investment, with a valuation of more than RMB 5 billion, and the investors include Sequoia China, Wuyuan Capital, PICC Capital and other head funds.

In summary, Dosage Pharma has become a leader in the biopharmaceutical field with its unique AI technology, wide range of design space, continuous innovation capability and industry recognition.